Today before the opening
bell, CytRx reported that it has appointed Dr. Shanta Chawla as its Vice
President of Clinical Development. Dr. Chawla brings to CytRx more than 13
years of experience in clinical research, operations, and development, with an
orientation toward oncology therapeutics. She will be assisting with the
management of global Phase 3 clinical trial that will examine aldoxorubicin as
a second-line treatment for soft tissue sarcomas.
“In this new position, Dr.
Chawla will play a key role in the management of our upcoming global Phase 3
clinical trial under a Special Protocol Assessment with aldoxorubicin as a
second-line treatment for soft tissue sarcomas,” said CytRx Executive Vice President
and Chief Medical Officer Dr. Daniel Levitt. “She has designed and managed
large clinical trials in North America and Europe for a range of cancer types,
and brings to CytRx a proven ability to meet enrollment targets and work within
budget requirements. We are fortunate to have Dr. Chawla join our team as we
move into a very exciting and demanding phase of activity.”
“I am delighted to be
joining CytRx at this critical point in the company’s development, and in
particular in light of the recently announced highly positive results from the
global Phase 2b trial with aldoxorubicin in advanced soft tissue sarcomas,”
said Dr. Chawla. “I look forward to playing a significant role in the continued
development of this promising oncology therapeutic.”
Dr. Chawla attained her
medical doctor degree from Maulana Azad Medical College in New Delhi. She
performed her internship and residency in Philadelphia at Albert Einstein
Medical Center and Thomas Jefferson University Hospital, respectively. Holding
a board certification, Dr. Chawla spent 2001 to 2013 at Spectrum
Pharmaceuticals, at which she most recently served as Vice President of
Clinical Research and Development. In that capacity, she specialized in
selection of clinical trial sites and principal investigators, establishment of
protocols with the FDA and key opinion leaders, preparation of FDA filings, and
project team management, among other functions she performed aptly.
Dr. Shanta Chawla is not
related to Dr. Sant Chawla, the principal investigator in CytRx’s global Phase
3 clinical trial for soft tissue sarcoma. As a cancer that arises in muscle
tissue, fat, blood vessels, tendons, fibrous tissues, and connective tissue,
soft tissue sarcoma was diagnosed in 11,400 new cases in the United States and identified
as being responsible for 4,400 deaths in the United States. Over 50 types of
soft tissue sarcoma have been found to exist, and this cancer can afflict the
body at any age.
For more information, visit:
www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
